ILMN heads into the final week of June with a striking divergence: options traders are the most bullishly positioned they've been in over a year, while short sellers have spent the past month quietly adding exposure — setting up an unusual two-way tension ahead of July 30 earnings.
The options market tells the most charged story this week. Call demand has surged relative to puts, driving the put/call ratio to 0.30 — nearly three standard deviations below its 20-day average of 0.40 and within touching distance of its 52-week low of 0.15. That's the most one-sided call skew in at least a year, suggesting options traders are aggressively positioned for upside continuation after a 14% gain in the past month. The stock closed at $164.93 on Tuesday, up 2.2% on the day and just fractionally ahead on the week.
Short positioning tells a different story. Bears have been rebuilding steadily — short interest has climbed roughly 25% over the past 30 days to 5.35% of the free float, the highest level in the dataset. The weekly move was actually small, down less than 1%, but the monthly trend is clear: from around 6.6 million shares shorted in late May to 8.2 million now. Despite that build, the borrow market remains loose. Availability runs well above 1,000% of current short interest, meaning lenders have no shortage of stock to place. Cost to borrow is 0.55%, up 43% over the month but still low in absolute terms. There is no squeeze pressure here — this is a deliberate, unhurried short rebuild against a rising stock, not a distressed position.
The Street is divided but shifting. JP Morgan's upgrade to Overweight on June 10 — lifting its target from $125 to $185 — was the most consequential move in recent weeks and brought a prominent voice into the bull camp just as the stock was breaking higher. Barclays, filing today, maintained its Underweight but raised its target from $122 to $145, an implicit acknowledgment that the downside case has narrowed. Guggenheim holds a Buy with a $180 target. At the other end, Citigroup keeps a Sell with a $95 target, and Canaccord trimmed to $140 Hold in May. The consensus mean price target of approximately $150 now sits below the current price — a signal the stock has outrun the average analyst's expectations, even as the bulls cluster well above it. The valuation story reflects the same tension: the price-to-book has risen nearly 13% over 30 days, and the trailing PE has expanded by roughly 11 points in the same window.
Institutional flows add one notable wrinkle. Keith Meister, the activist investor who has been a prominent Illumina holder via Corvex Management, sold roughly 132,000 shares across two trades on June 1 — a combined $21.5 million exit — reducing his disclosed position to 2.84 million shares. Corvex's holding is listed as unchanged in the institutional table, but Meister's personal register shows a near-million-share reduction. That's a material trim from the activist who helped push through the Grail divestiture. BlackRock and Capital Research both added in the most recent period, and the holder count of 356 institutions keeps the register broadly supported.
The next hard catalyst is the Q1 results on July 30. The prior earnings print on April 30 produced a 12.8% single-day gain and a 15.2% five-day rally — the kind of move that explains why call buyers are active now. With short interest at a 30-day high, call positioning at a 52-week bullish extreme, and the stock trading above most analyst targets, July 30 is shaping up as the moment where the divergence between cautious shorts and aggressive call buyers has to resolve.
See the live data behind this article on ORTEX.
Open ILMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
